Total Cost Of Cancer Care Research Articles

Pancreatic diseases.

Pancreatic diseases.

The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Radiotherapy for Cancer including a Prospective Survey of Radiotherapy Practice in Sweden 2001--Summary and Conclusions

A systematic assessment of radiotherapy for cancer was conducted by The Swedish Council on Technology Assessment in Health Care (SBU) and published in 1996. The assessment reviewed the scientific literature up to 1993 on the use of radiotherapy in the treatment of solid tumours, and estimated the costs associated with radiotherapy. It also described the current practise of radiotherapy in Sweden 1992 and compared practise with scientific knowledge. The SBU has now conducted a follow-up study on radiotherapy for cancer, including a review of the scientific literature from 1994 and a prospective survey of radiotherapy practise in Sweden 2001. The following conclusions were drawn: <list id="l1" type="5"> <item>The role of radiotherapy as an important form of treatment for cancer with both curative and palliative intent has been further confirmed.</item><item>The use of radiotherapy in Sweden has increased and is now at the internationally recommended level.</item><item>Radiotherapy in Sweden is mostly given in accordance with the scientific evidence but may still be underutilized in certain situations.</item><item>The resources for radiotherapy are being utilized more efficiently.</item><item>The costs of radiotherapy are still 5% of the total cost of cancer care, while the cost of an individual treatment (fraction) has decreased.</item><item>The need for radiotherapy capacity will increase. In addition, half of the treatment equipment will have to be replaced in the next few years.</item></list>

‘Ground-breaking’ data on ‘real-world’ total costs of cancer treatment

Cancer is a very costly disease that is continuing to increase in prevalence - approximately 1.4 million new cases of cancer were diagnosed in the US in 1996. However, accurate data on the total costs of cancer care are lacking because of the limitations of existing healthcare databases. Professor Jim Koeller, from the University of Texas, US, presented some ‘ground-breaking’ research on the ‘real-world’ total direct costs of treating non-small-cell lung cancer (NSCLC) at the American Society of Health-System Pharmacists’ (ASHP) Annual Meeting [Minneapolis, US; June 1997]. Professor Koeller and colleagues have also assessed the total direct costs of treating ovarian and small-cell lung cancers. Results of their prospective study showed that total cost data cannot be extrapolated from one type of cancer to another.